Press Releases

We’re Delivering the Promise of Healthier Lives.

CURE PHARMACEUTICAL 

Press Releases

We specialize in optimal formulations to achieve targeted release and exposure of medications.​

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES – February 12, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both […]

read more
CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines  Oxnard, Calif. February 5, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups […]

read more
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

OXNARD, Calif., November 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward […]

read more
CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds […]

read more
CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

Biopharma star brings extensive translational research experience as company advances its clinical indications Oxnard, Calif. – October 1, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its Chief Scientific Officer. In this role, Dr. Gigi will oversee all CURE’s research and development. Dr. Gigi […]

read more
CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

OXNARD, Calif. – August 21, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, […]

read more
CURE Pharmaceutical Expands Board with Two Women Directors

CURE Pharmaceutical Expands Board with Two Women Directors

Oxnard, Calif. – August 7, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both […]

read more
CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

OXNARD, Calif. – July 24, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using its proprietary drug delivery […]

read more
CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

OXNARD, Calif. – July 16, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With an increased consumer demand […]

read more

CURE Pharmaceutical and Canopy Growth To Produce CBD Oral Thin Films 

OXNARD, Calif. – June 19, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm license gives […]

read more